🧾 What This Document Is

This is a 6-K form, which is a report U.S. listed foreign companies like Innate Pharma use to announce major news to investors. Think of it as an official press release filed with the SEC.

The news here is simple: Innate Pharma's executives will be attending an investor conference to meet one-on-one with potential investors. It's a routine but important piece of corporate communication.

🏢 What The Company Does

👉 In simple terms, Innate Pharma is a biotech "engine room" building new ways for the immune system to fight cancer. They are not a big pharmaceutical company selling drugs yet; they are a clinical-stage company, meaning their main products are still being tested in patients.

They focus on creating sophisticated antibody therapeutics—smart proteins designed to find and attack cancer cells. Their strategy involves both developing their own drugs and forming partnerships with giants like AstraZeneca and Sanofi to help fund and advance the research.

🚀 Key Moves & Pipeline

The company highlighted three of its leading drug candidates, which show its strategic focus:

• IPH4502: A "differentiated Nectin-4 ADC" for solid tumors. ADCs are like guided missiles that attach to cancer cells and deliver a potent drug inside.
• Lacutamab: An antibody targeting a marker called KIR3DL2. It's being developed for specific types of rare blood cancers: cutaneous T-cell lymphomas (CTCL) and peripheral T-cell lymphomas (PTCL).
• Monalizumab: An anti-NKG2A antibody. This is a key asset being developed in collaboration with AstraZeneca for non-small cell lung cancer (NSCLC), one of the most common cancer types.

👉 Why it matters: This pipeline shows they are betting on several different innovative approaches to cancer, from direct attacks (ADCs) to immune system modulators. The AstraZeneca partnership for monalizumab is especially important—it validates their science and provides crucial funding and expertise.

💰 Financial Position & Listing

While this filing doesn't include financial results, it reminds us of Innate Pharma's corporate structure. They are dual-listed on:

• Euronext Paris (Ticker: IPH)
• Nasdaq in the U.S. (Ticker: IPHA)

This dual listing gives them access to both European and American investors, which can be vital for funding their expensive research and development. Their headquarters are in Marseille, France, with a U.S. office in Rockville, MD.

📅 The Event & Why It Matters

The specific news is their participation in the Kempen Life Sciences Conference in Amsterdam on April 15-16, 2026. Their executive team will hold one-on-one investor meetings.

👉 Why it matters: For a clinical-stage biotech like Innate, investor conferences are crucial. These meetings are where they can:

1. Update sophisticated investors on their clinical trial progress.
2. Build relationships that could lead to future funding rounds.
3. Potentially attract a new strategic partner for one of their drug candidates. It's a key part of managing the business side while the science advances in the lab and clinic.

⚖️ Big Picture

👍 Strengths:

• Diversified Pipeline: They are working on multiple promising approaches (ADCs, antibodies) across different cancers.
• Strategic Collaborations: Partnerships with AstraZeneca and Sanofi provide validation, funding, and de-risk development.
• Expertise: They have deep expertise in antibody engineering, a critical and complex area of modern cancer drug development.

⚠️ Risks:

• Clinical Stage: The company is not yet profitable. Its future value depends almost entirely on whether its drug candidates successfully pass clinical trials and get approved—a process that is long, expensive, and has a high failure rate.
• Regulatory Hurdles: All new drugs face strict scrutiny from regulators like the FDA and EMA.
• Funding Needs: They will likely need to raise more capital in the future to fund late-stage trials, which could dilute existing shareholders.

🧠 The Analogy

Think of Innate Pharma as a high-end specialty engine builder for race cars. They don't race the cars themselves (sell drugs), but they design and prototype incredibly advanced engines (immunotherapies). They partner with major racing teams (AstraZeneca, Sanofi) to test and refine their engines on the track (clinical trials), hoping one day their engine will win the championship (become an approved, blockbuster cancer treatment). Their conference appearance is like presenting their latest engine designs to potential new investors and racing teams.

📇 Key Contacts & People

The filing does not list specific contact people for this announcement. For general inquiries, the company provides:

• Website: www.innate-pharma.com
• Social Media: LinkedIn and X (formerly Twitter)

Corporate Information:

• Headquarters: Marseille, France
• U.S. Office: Rockville, MD
• ISIN Code: FR0010331421
• Euronext Ticker: IPH
• Nasdaq Ticker: IPHA
• LEI: 9695002Y8420ZB8HJE29

🧩 Final Takeaway

This filing is a brief, routine update showing Innate Pharma is actively engaged with the investment community. The underlying story is that of a promising but high-risk clinical-stage biotech, leveraging its scientific expertise and big-pharma partnerships to advance a diverse pipeline of next-generation cancer fighters toward the market.